The bioengineered skin substitutes market has seen considerable growth due to a variety of factors.
• The market for bioengineered skin substitutes has experienced quick expansion in the previous few years. The market size is projected to escalate from $2.18 billion in 2024 to $2.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.7%.
The significant growth during the past period can be primarily attributed to the escalating investments in research and development, enhancement in healthcare facilities, growth in the number of reconstructive and cosmetic surgical procedures, elevation in healthcare expenditure, and better patient results.
The bioengineered skin substitutes market is expected to maintain its strong growth trajectory in upcoming years.
• The market for bioengineered skin substitutes is projected to experience a significant surge in the coming years. The market is expected to hit a valuation of $4.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.5%.
Contributing factors to the predicted growth during the forecasted period include the creation of novel biomaterials, regulatory advancements, government actions and financial support, cost-effectiveness accompanied by long-term advantages, and an increase in aesthetic and reconstructive surgeries. Key trends during this forecasted span are likely to revolve around regulatory policies, advanced biomaterial developments, cellular-focused measures, improved vascularization techniques, and innovative biofabrication methodologies.
The bioengineered skin substitute market is poised for growth, driven by the increasing incidence of burn injuries. These are injuries that result from damage to the skin or other bodily tissues, primarily induced by heat, radiation, chemicals, electricity, or friction. There is a frequent occurrence of these burn cases, often due to a lack of safety awareness, improper use of combustible materials, and disregard for fire risks and safety procedures. Bioengineered skin substitutes present either a temporary or permanent solution for injured skin. They aid in the healing process, minimize infection risk, and enhance functional and aesthetic results. For instance, data from an inpatient care evaluation published by the American Burn Association, a non-profit US-based organization, in November 2023, revealed 30,135 cases of burns in the U.S. in 2022. This makes up a five-year tally of 152,312 cases, with an estimated one per 10,000 requiring inpatient treatment at a burn center each year. Consequently, the growth of the bioengineered skin substitute market is driven by the escalating number of burn injuries.
The bioengineered skin substitutesmarket covered in this report is segmented –
1) By Product: Acellular, Allogeneic, Xenogeneic, Autologous, Other Products
2) By Application: Acute Wounds, Chronic Wounds
3) By End User: Wound Care Centers, Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Acellular Skin Substitutes: Acellular Dermal Matrix, Acellular Epidermal Matrix
2) By Allogeneic Skin Substitutes: Allogeneic Dermal Grafts, Allogeneic Epidermal Grafts
3) By Xenogeneic Skin Substitutes: Porcine-Derived Skin Substitutes, Bovine-Derived Skin Substitutes
4) By Autologous Skin Substitutes: Autologous Skin Grafts, Cultured Autologous Skin Cells
5) By Other Products: Bi-layered Skin Substitutes, Bioactive Skin Substitutes, Synthetic Skin Substitutes
Top-notch companies in the bioengineered skin substitute market are innovating with fish skin grafts to boost their effectiveness and adaptability. A graft made from fish skin is a material that aids in wound healing by promoting tissue regeneration and restoration. An example of this occurred in February 2024 when the Iceland-based wound care firm Kerecis introduced Shield Standard, a bioengineered skin substitute. This product marries raw fish skin with a silicone backing, providing a natural scaffold for healing. Kerecis utilizes a patented technology which minimally processes the fish skin to preserve the beneficial elements that aid tissue regeneration. This skin substitute has distinctive attributes, such as its compatibility with human skin, natural ability to retain moisture, minimized risk of infection, making it a prospective choice for handling diverse wounds, encompassing chronic and acute injuries.
Major companies operating in the bioengineered skin substitutes market are:
• Stryker Corporation
• DePuy Synthes
• Smith & Nephew Plc
• ConvaTec Group PLC
• Mallinckrodt Pharmaceuticals plc
• Integra LifeSciences Holdings Corporation
• Gunze Limited
• Organogenesis Inc.
• LifeNet Health Inc.
• MiMedx Group Inc.
• Vericel Corporation
• AlloSource Inc.
• Sientra Inc.
• PolyNovo Limited
• Avita Medical Limited
• Tissue Regenix Group
• Amarantus Bioscience Holdings Inc.
• PolarityTE
• Promethean LifeSciences Inc.
• Regenicin Inc.
North America was the largest region in the bioengineered skin substitutes market in 2024. The regions covered in the bioengineered skin substitutes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.